CClinicalTrials.gg
CompletedNCT03166345PRPITMUpdated Jul 12, 2018

Use of Platelet Rich Plasma (PRP) for Improving Thin Endometrium

An interventional study of Treatment of Thin Endometrium in Poor Endometrium, sponsored by Ibn Sina Hospital. Completed at 2 sites in Egypt. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by Ibn Sina Hospital · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Platelets rich plasma is simple source of growth factors and cytokines that can regulate endometrial growth for subgroup of thin endometrium women. It is an autologous source of this enhancing factors; therefore, there os no risk of using it within the same participant.

02

Conditions studied

  • Poor Endometrium
03

In context

Lead sponsor

Ibn Sina Hospital is the lead sponsor of 28 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • women with thin endometrium

Exclusion criteria

Exclusion Criteria:

  • serum positive hepatitis B and C women
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    PRP injection into Uterine Cavity

    PRP injection into Uterine Cavity For Treatment of Thin Endometrium

    Other: Treatment of Thin Endometrium

  • Experimental
    CSF (colony stimulating factor)

    CSF for Treatment of Thin Endometrium

    Other: Treatment of Thin Endometrium

  • No intervention
    No intervention

    The control arm.

Interventions

  • OtherTreatment of Thin Endometrium

    This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.

06

What researchers measure

Primary outcomes

  1. Mean Diameter of endometrial thickness

    How the endometrium would respond after 2 days of PRP

    Time frame: 2 days

Secondary outcomes

  1. Clinical pregnancy rate

    Registered fetal heartbeat 4 weeks or beyond after embryo transfer.

    Time frame: 4 weeks or beyond after embryo Transfer

07

Study locations

2 sites
  • Gannah IVF unit, Gannah Hospital
    Giza, 12345, Egypt
  • IbnSina IVF Center, IbnSina Hospital
    Sohag, 12345, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03166345
Lead sponsor
Ibn Sina Hospital
Collaborators
Ganna Hospital
Responsible party
Muhammad Fawzy (IVF Lab Director, Ibn Sina Hospital) — Principal investigator
First posted
May 25, 2017
Start date
Aug 15, 2017
Primary completion
Mar 30, 2018
Completion
Apr 1, 2018
Last update
Jul 12, 2018

Study contacts

Ayman S El-Gohary, MD
principal investigator · Ganna Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion